Management team

Antti Vuolanto

Chief Executive Officer

CEO Antti Vuolanto, DSc, started in his current role in July 2022. He joined Herantis Pharma Plc in February 2018 as COO. Antti has vast experience in research, development, and manufacturing of biological drugs, as well as from senior management positions in early-stage biotech companies. Previously he served as COO at Valo Therapeutics, Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.

Tone Kvåle

Chief Financial Officer

CFO Tone Kvåle joined Herantis in October 2020 and she has more than 25 years of experience from the biotech and life sciences industry. She was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that, she held CFO roles at NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher. In these roles, she helped raise over EUR 200m in financing, was involved in IPO’s and M&A’s and was responsible for financial reporting under various reporting standards including US GAAP and IFRS. She is currently board director and chair of the audit committee of Bonesupport AB, Sweden. Tone has a diploma in finance and administration from UiT, The Arctic University of Norway, Harstad. She has completed the prescribed course of study and the examination for Advanced Programme in Corporate Finance at The Norwegian School of Economics, NHH.

Henri Huttunen

Chief Scientific Officer

CSO Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. While he was an adjunct professor, Dr. Huttunen lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.

Sigrid Booms

Head of Regulatory Affairs & Compliance

Head of Regulatory Affairs and Compliance, Sigrid Booms has been at Herantis since August 2011. Mrs. Booms has more than 25 years of experience in global development of pharmaceuticals for human use, with previous positions in regulatory affairs at Orion Pharma and at a global clinical CRO as Director, Regulatory Affairs. During her career, she was involved in several drug development projects in the CNS therapeutic area, including leading CDNF through the Phase 1-2 clinical study in Parkinson’s disease for Herantis. Over the years she has become a specialist in regulatory aspects for nonclinical and early phase clinical development. Mrs. Booms holds a Licentiate in Pharmacy from the University of Utrecht in the Netherlands.

Charlotte Videbæk

Vice President Clinical Development

Charlotte Videbæk, MD is the Vice President Clinical Development since April 2022. Dr. Videbæk is a board-certified neurologist from Copenhagen with a track record from international pharmaceutical companies developing therapies for neurodegenerative diseases, including Parkinson’s disease.  She has worked at Novartis and Roche in Basel prior to joining Lundbeck in Copenhagen in various positions including VP Corporate Project Management R&D. Lately she has been with earlier stage companies and focused on entrepreneurship. Charlotte is a board director of Cessatech A/S, Tissue-Link and consultant and founder of C-ApS.